EXEL

$EXEL

Exelixis, Inc.

Oncology-focused biotech company with Cabometyx for kidney and liver cancers.

Healthcare
$65.83
-2.46 (-3.60%)
Day Range$65.36 - $68.50
Prev Close$68.29

EXEL key facts as of November 14, 2026

Latest AI research report
EXEL Stock Outlook: Zanza Catalysts and Valuation (as of November 14, 2026)
StockAlpha report sentiment
Neutral (as of November 14, 2026)
Analyst consensus
Hold (1 Strong Buy, 5 Buy, 10 Hold, 0 Sell, 1 Strong Sell) (as of November 1, 2026)
Analyst price target
$54.20 mean (range $49.00 to $65.00) (as of November 20, 2026)
Sector
Healthcare
Analyst Rating
Hold
6 Buy / 10 Hold / 1 Sell
Price Target
$54.20
-17.7% downside
Subscribers
0
Tracking this ticker
Latest Report

Analysis from Nov 14, 2026

NEUTRAL

EXEL Stock Outlook: Zanza Catalysts and Valuation

Exelixis enters the next phase of its cancer-drug pipeline with zanzalintinib regulatory and clinical events expected by early 2027. Profitable growth and a recent earnings beat are balanced by a share price above the supplied analyst target range midpoint and the risks of drug development.

Nov 14, 2026

EXEL FAQ

What is StockAlpha's latest view on EXEL?

StockAlpha's latest AI research report on Exelixis, Inc. (EXEL), "EXEL Stock Outlook: Zanza Catalysts and Valuation", was published on November 14, 2026 and rates the overall sentiment as neutral. Exelixis enters the next phase of its cancer-drug pipeline with zanzalintinib regulatory and clinical events expected by early 2027. Profitable growth and a recent earnings beat are balanced by a share price above the supplied analyst target range midpoint and the risks of drug development.

When was the EXEL research last updated?

The most recent EXEL report was published on November 14, 2026.

What do analysts expect for EXEL?

As of November 1, 2026, the analyst consensus on EXEL is Hold (1 Strong Buy, 5 Buy, 10 Hold, 0 Sell, 1 Strong Sell). As of November 20, 2026, the analyst price target is $54.20 mean (range $49.00 to $65.00).

Is this EXEL research investment advice?

No. StockAlpha.ai research is AI-generated analysis for informational purposes only and is not investment advice. Analyst figures are third-party data. Do your own research before making investment decisions.

Keep exploring